Capital Group Private Client Services Inc. Decreases Position in Amgen Inc. $AMGN

Capital Group Private Client Services Inc. reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 77.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 69,412 shares of the medical research company’s stock after selling 236,525 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Amgen were worth $19,588,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Capital Group Investment Management PTE. LTD. raised its stake in shares of Amgen by 93.4% during the third quarter. Capital Group Investment Management PTE. LTD. now owns 11,732 shares of the medical research company’s stock valued at $3,311,000 after purchasing an additional 5,666 shares during the period. Bank of Montreal Can grew its holdings in Amgen by 5.3% during the 3rd quarter. Bank of Montreal Can now owns 1,063,079 shares of the medical research company’s stock valued at $300,001,000 after purchasing an additional 53,566 shares in the last quarter. Legal & General Group Plc increased its stake in Amgen by 5.0% during the 3rd quarter. Legal & General Group Plc now owns 3,716,957 shares of the medical research company’s stock worth $1,048,925,000 after buying an additional 177,325 shares during the period. Pinkerton Wealth LLC lifted its holdings in Amgen by 11.5% in the 3rd quarter. Pinkerton Wealth LLC now owns 17,976 shares of the medical research company’s stock worth $5,073,000 after buying an additional 1,850 shares in the last quarter. Finally, Banque Cantonale Vaudoise boosted its position in Amgen by 2.3% in the 3rd quarter. Banque Cantonale Vaudoise now owns 17,333 shares of the medical research company’s stock valued at $4,892,000 after buying an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AMGN. Oppenheimer set a $400.00 price target on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Guggenheim lifted their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Finally, Wells Fargo & Company upped their price objective on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $354.17.

Amgen Stock Up 2.0%

Shares of Amgen stock opened at $376.97 on Tuesday. The stock has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The business’s 50 day simple moving average is $354.21 and its 200-day simple moving average is $323.38.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.